South Korea · Delayed Price · Currency is KRW GC Biopharma Statistics
Total Valuation
GC Biopharma has a market cap or net worth of KRW 1.51 trillion. The enterprise value is 2.73 trillion.
| Market Cap | 1.51T |
| Enterprise Value | 2.73T |
Important Dates
The next estimated earnings date is Friday, November 14, 2025.
| Earnings Date | Nov 14, 2025 |
| Ex-Dividend Date | Dec 27, 2024 |
Share Statistics
GC Biopharma has 11.41 million shares outstanding.
| Current Share Class | 11.41M |
| Shares Outstanding | 11.41M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.94% |
| Owned by Institutions (%) | 16.40% |
| Float | 5.45M |
Valuation Ratios
The trailing PE ratio is 20.45 and the forward PE ratio is 25.61.
| PE Ratio | 20.45 |
| Forward PE | 25.61 |
| PS Ratio | 0.84 |
| PB Ratio | 1.03 |
| P/TBV Ratio | 1.76 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 14.10, with an EV/FCF ratio of -32.57.
| EV / Earnings | 37.08 |
| EV / Sales | 1.53 |
| EV / EBITDA | 14.10 |
| EV / EBIT | 25.66 |
| EV / FCF | -32.57 |
Financial Position
The company has a current ratio of 1.19, with a Debt / Equity ratio of 0.76.
| Current Ratio | 1.19 |
| Quick Ratio | 0.44 |
| Debt / Equity | 0.76 |
| Debt / EBITDA | 7.45 |
| Debt / FCF | -13.38 |
| Interest Coverage | 1.38 |
Financial Efficiency
Return on equity (ROE) is 3.52% and return on invested capital (ROIC) is 1.59%.
| Return on Equity (ROE) | 3.52% |
| Return on Assets (ROA) | 1.36% |
| Return on Invested Capital (ROIC) | 1.59% |
| Return on Capital Employed (ROCE) | 3.37% |
| Revenue Per Employee | 876.47M |
| Profits Per Employee | 36.07M |
| Employee Count | 2,042 |
| Asset Turnover | 0.61 |
| Inventory Turnover | 1.66 |
Taxes
| Income Tax | -3.58B |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -12.67% in the last 52 weeks. The beta is 1.05, so GC Biopharma's price volatility has been similar to the market average.
| Beta (5Y) | 1.05 |
| 52-Week Price Change | -12.67% |
| 50-Day Moving Average | 135,236.00 |
| 200-Day Moving Average | 135,759.00 |
| Relative Strength Index (RSI) | 46.51 |
| Average Volume (20 Days) | 33,716 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, GC Biopharma had revenue of KRW 1.79 trillion and earned 73.65 billion in profits. Earnings per share was 6,453.27.
| Revenue | 1.79T |
| Gross Profit | 533.55B |
| Operating Income | 63.40B |
| Pretax Income | 48.48B |
| Net Income | 73.65B |
| EBITDA | 150.60B |
| EBIT | 63.40B |
| Earnings Per Share (EPS) | 6,453.27 |
Balance Sheet
The company has 85.61 billion in cash and 1.12 trillion in debt, giving a net cash position of -1,036.40 billion or -90,807.31 per share.
| Cash & Cash Equivalents | 85.61B |
| Total Debt | 1.12T |
| Net Cash | -1,036.40B |
| Net Cash Per Share | -90,807.31 |
| Equity (Book Value) | 1.47T |
| Book Value Per Share | 112,133.29 |
| Working Capital | 236.42B |
Cash Flow
In the last 12 months, operating cash flow was -47.83 billion and capital expenditures -36.02 billion, giving a free cash flow of -83.85 billion.
| Operating Cash Flow | -47.83B |
| Capital Expenditures | -36.02B |
| Free Cash Flow | -83.85B |
| FCF Per Share | -7,346.71 |
Margins
Gross margin is 29.81%, with operating and profit margins of 3.54% and 4.12%.
| Gross Margin | 29.81% |
| Operating Margin | 3.54% |
| Pretax Margin | 2.71% |
| Profit Margin | 4.12% |
| EBITDA Margin | 8.41% |
| EBIT Margin | 3.54% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 1,500.00, which amounts to a dividend yield of 1.14%.
| Dividend Per Share | 1,500.00 |
| Dividend Yield | 1.14% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 25.57% |
| Buyback Yield | n/a |
| Shareholder Yield | 1.14% |
| Earnings Yield | 4.89% |
| FCF Yield | -5.57% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on June 7, 2013. It was a forward split with a ratio of 1.05.
| Last Split Date | Jun 7, 2013 |
| Split Type | Forward |
| Split Ratio | 1.05 |
Scores
GC Biopharma has an Altman Z-Score of 1.72 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.72 |
| Piotroski F-Score | 5 |